Rhythm Pharmaceuticals (RYTM)
(Delayed Data from NSDQ)
$88.57 USD
-1.67 (-1.85%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $88.56 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Rhythm Pharmaceuticals, Inc.'s return on equity, or ROE, is -739.62% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.42%. While this shows that RYTM has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
RYTM 88.57 -1.67(-1.85%)
Will RYTM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RYTM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RYTM
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
RYTM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to Decline
RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates
Other News for RYTM
Rhythm Pharmaceuticals Inc (RYTM) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Rhythm Pharmaceuticals (RYTM) Target Price Increased by Morgan Stanley
Rhythm Pharmaceuticals price target raised by $9 at Morgan Stanley, here's why
Q2 2025 Rhythm Pharmaceuticals Inc Earnings Call Transcript
Rhythm (RYTM) Forecasts 2025 Non-GAAP Operating Expenses